An Open-label Phase II Trial Evaluating the Efficacy and Safety of Sintilimab Plus Anlotinib Combined With Chemotherapy as Neoadjuvant Therapy in Early-stage Triple-negative Breast CancerNeoSACT
Latest Information Update: 14 Feb 2024
At a glance
- Drugs Carboplatin (Primary) ; Catequentinib (Primary) ; Cyclophosphamide (Primary) ; Epirubicin (Primary) ; Paclitaxel (Primary) ; Sintilimab (Primary)
- Indications Advanced breast cancer; Early breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- Acronyms NeoSACT
- 13 Jul 2023 Planned number of patients changed from 46 to 31.
- 13 Feb 2023 Planned End Date changed from 31 Dec 2024 to 31 Dec 2025.
- 13 Feb 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.